Moderna-Merck mRNA Cancer Vaccine Cuts Melanoma Recurrence — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Moderna and Merck developed a personalized mRNA vaccine that, with pembrolizumab, cut melanoma recurrence or death by a significant margin in a trial of over 1,100 patients.
- Trial participants receiving the vaccine plus pembrolizumab had a 82% recurrence-free survival rate at two years, compared to 70% for those on pembrolizumab alone.
- Rebecca Lee says the vaccine contains up to 34 cancer-specific mutations encoded in mRNA, acting as a 'fingerprint' to train T-cells to better recognize and attack tumors.
- Alan Melcher notes the combined endpoint of recurrence or death primarily reflects reduced recurrence, as cancer must return before causing death in this context.
- James Larkin suggests the vaccine platform could extend to lung, bladder, and kidney cancers, which are also treated with immunotherapy.
- Rebecca Lee warns the bespoke manufacturing process will make the vaccine very costly—potentially around $200,000 per treatment—raising doubts about NHS affordability.
Why it matters: Thousands of high-risk melanoma patients in the UK and US could gain access to a vaccine that meaningfully reduces recurrence, but at an estimated $200,000 per dose, health systems like the NHS may delay adoption due to cost-effectiveness concerns, limiting equitable access despite clinical success.
Ask SkimNews
